Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
Public ClinicalTrials.gov record NCT02708186. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia With Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study seeks to evaluate the safety and efficacy of Nelotanserin for the treatment of Rapid Eye Movement (REM) Sleep Behavior Disorder (RBD) in subjects with dementia with Lewy bodies (DLB) or Parkinson's disease dementia (PDD).
Study identification
- NCT ID
- NCT02708186
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 34 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2016 (Actual)
- Primary completion
- May 2018 (Actual)
- Completion
- May 2018 (Actual)
- Last update posted
- May 20, 2020
2016 – 2018
United States locations
- U.S. sites
- 23
- U.S. states
- 15
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| US120 | Birmingham | Alabama | 35294 | — |
| US164 | Phoenix | Arizona | 85013 | — |
| US145 | Sun City | Arizona | 85351 | — |
| US143 | Little Rock | Arkansas | 72205 | — |
| US122 | Englewood | Colorado | 80113 | — |
| US180 | Maitland | Florida | 32751 | — |
| US154 | Ocala | Florida | 34471 | — |
| US113 | Orlando | Florida | 32806 | — |
| US152 | Ormond Beach | Florida | 32174 | — |
| US153 | Tampa | Florida | 33613 | — |
| US163 | Atlanta | Georgia | 30331 | — |
| US107 | Indianapolis | Indiana | 46202 | — |
| US132 | Lenexa | Kansas | 66214 | — |
| US129 | Lincoln | Nebraska | 68526 | — |
| US101 | Chapel Hill | North Carolina | 27514 | — |
| US159 | New Bern | North Carolina | 28562 | — |
| US147 | Fargo | North Dakota | 58103 | — |
| US111 | Cincinnati | Ohio | 45229 | — |
| US104 | Cleveland | Ohio | 44195 | — |
| US105 | Columbus | Ohio | 43210 | — |
| US173 | Lincoln | Rhode Island | 02865 | — |
| US128 | Memphis | Tennessee | 38613 | — |
| US131 | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02708186, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 20, 2020 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02708186 live on ClinicalTrials.gov.